Morepen Laboratories Limited announced the launch of four new products in April 2025:

• Ticapen (Ticagrelor 60mg/90mg) for cardiovascular care.
• UdoFix (Ursodeoxycholic Acid 150/300mg) for liver health, featuring 98.23% superior dissolution and competitive pricing (₹39.9/tab).
• LycoMore Syrup, a nutraceutical blend for immunity and recovery.
• Acifix Raft Suspension for GERD, reflux, and heartburn relief with a unique paan flavor. These products, targeting the domestic market, utilize APIs manufactured in-house at Morepen's USFDA-approved plants.

This launch is a strategic step to scale Morepen's finished dosages business, which is currently approximately ₹325 crore. The company aims to accelerate towards a target of ₹1,000 crore over the next five years, driven by deeper market penetration and an expanded portfolio. Morepen highlighted its position as India's #1 exporter of APIs for six global molecules, with a presence in 82 countries and an annual API capacity of 144 metric tons, leveraging its integrated capabilities.